Twelve-month real-world outcomes of sparsentan in a multicentre Spanish IgA nephropathy cohort

Clicks: 22
ID: 327053
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #81 of 228 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 228 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Sparsentan has demonstrated significant antiproteinuric effects in randomized trials of IgA nephropathy (IgAN). However, real-world evidence remains scarce and is largely limited to short-term follow-up. Data on the durability of the antiproteinuric response in routine clinical practice are still lacking. Methods This multicenter retrospective study included patients with biopsy-proven IgAN treated with sparsentan in routine clinical practice across Spanish centers. Patients were eligible if they initiated sparsentan outside a clinical trial and had at least 3 months of follow-up. The primary outcome was the proportion of patients achieving a >50% reduction in proteinuria at 3 months (responders). Secondary outcomes included changes in proteinuria and kidney function at 6 and 12 months, as well as safety. Results A total of 41 patients were included. The median age was 42 years, with a median baseline eGFR of 44 mL/min/1.73 m² and 95% receiving concomitant SGLT2 inhibitors. Median baseline proteinuria was 1163 mg/24h. At 3 months, proteinuria decreased to 772 mg/24h (median reduction 44.1%), with 51% of patients achieving a >50% reduction. Among patients with extended follow-up, the antiproteinuric effect was sustained at 6 months (median reduction 46.9%) and persisted at 12 months (median reduction 38.9%), despite increased variability. Notably, kidney function remained stable throughout follow-up, despite a moderately reduced baseline eGFR. No clinically relevant hyperkalemia or severe adverse events were observed. Conclusions In this multicenter real-world Spanish cohort, sparsentan was associated with a sustained reduction in proteinuria in patients with biopsy-proven IgAN, maintained up to 12 months, along with preserved kidney function even in those with moderately reduced baseline eGFR, and a favorable safety profile. These findings support the effectiveness of sparsentan on top of contemporary standard of care and provide early evidence of sustained benefit in routine clinical practice.
Reference Key
openalex_W7204941858 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Clara García-Carro, Antolina Rodríguez-Moreno, Lucia Cordero, María Vanessa Pérez-Gómez, Helena Marco Rusiñol, Enrique Pasache, Alejandro Morales, Rocío Zamora, Diego Parra, Juan Villa, Elena Guillén, Verónica Coll-Brito, Álvaro Álvarez, Juliana Bordignon, Carola Arcal, Olga Gracia, Patricia Delgado, María José Soler, Ana Sánchez‐Fructuoso
Are you one of these authors? Claim your profile
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag298
URL
https://doi.org/10.1093/ckj/sfag298
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.